GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (XCNQ:LOBE) » Definitions » Loans Receivable

Lobe Sciences (XCNQ:LOBE) Loans Receivable : C$0.00 Mil (As of Nov. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lobe Sciences Loans Receivable?

Lobe Sciences's Loans Receivable for the quarter that ended in Nov. 2024 was C$0.00 Mil.


Lobe Sciences Loans Receivable Historical Data

The historical data trend for Lobe Sciences's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences Loans Receivable Chart

Lobe Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lobe Sciences Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lobe Sciences Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Lobe Sciences Loans Receivable Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Lobe Sciences Business Description

Traded in Other Exchanges
Address
1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease.

Lobe Sciences Headlines

No Headlines